Advertisement

Midodrine for Treatment of Vasovagal Syncope

  • D. G. Benditt
  • L. Wilbert
  • G. Fahy
  • S. Sakaguchi
  • K. G. Lurie
  • N. Samniah
Conference paper

Abstract

Most vasovagal fainters who seek medical attention require no more than the reassurance that their physician understands the basis of their symptoms, and education regarding both the nature of the problem and techniques which may avert recurrences. However, when spells are frequent, or are associated with physical injury, or threaten to compromise occupational status, prophylactic treatment measures become a consideration. Unfortunately, the optimum treatment approach remains uncertain.

Keywords

Cardiac Pace Vasovagal Syncope Unexplained Syncope Neurocardiogenic Syncope Upright Tilt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Almquist A, Goldenberg IF, Milstein S, Chen M-Y, Chen X-C, Hansen R, Gornick CC, Benditt DG (1989) Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med 320:346–351PubMedCrossRefGoogle Scholar
  2. 2.
    Fitzpatrick AP, Ahmed R, Williams S, Sutton R (1991) A randomised trial of medical therapy in “malignant vasovagal syndrome” or “neurally-mediated bradycardia hypotension syndrome”. Eur J Cardiac Pacing Electrophysiol 2:99–102Google Scholar
  3. 3.
    Brignole M, Menozzi C, Gianfranchi L, Lolli G, Bottoni N, Oddone D (1992) A controlled trial of acute and long-term medical therapy in tilt-induced neurally-mediated syncope. Am J Cardiol 70:339–342PubMedCrossRefGoogle Scholar
  4. 4.
    Mahanonda N, Bhuripanyo K, Kangkagate C, Wansanit K, Kulchot B, Nademanee K, Chaithiraphan S (1995) Randomized double-blind placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table results. Am Heart J 130:1250–1253PubMedCrossRefGoogle Scholar
  5. 5.
    Milstein S, Buetikofer J, Dunnigan A, Benditt DG, Gornick C, Reyes WJ (1990) Usefulness of disopyramide for prevention of upright tilt-induced hypotensionbradycardia. Am J Cardiol 65:1339–1344PubMedCrossRefGoogle Scholar
  6. 6.
    Morillo C, Leitch JW, Yee R, Klein GJ (1993) A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt J Am Coll Cardiol 22:1843–1848PubMedCrossRefGoogle Scholar
  7. 7.
    Kosinski DJ, Grubb BP, Temesy-Armos PN (1994) The use of serotonin re-uptake inhibitors in the treatment of neurally mediated cardiovascular disorders. J Serotonin Res 1:85–90Google Scholar
  8. 8.
    Grubb BP, Wolfe D, Samoil D, Temesy-Armos P, Hahn H, Elliott L (1993) Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol 16:458–464PubMedCrossRefGoogle Scholar
  9. 9.
    Sutton R, Brignole M, Raviele A, for the Vasis Group Investigators (1998) Randomised controlled trial of etilefrine therapy for vasovagal syncope. Arch Mal Coeur 91 (special III):242 (abstr)Google Scholar
  10. 10.
    Moya A, Permanyer-Miralda G, Sagrista-Sauleda J, Carne X, Rius T, Mont L, Soler Soler J (1995) Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo. J Am Coll Cardiol 25:65–69PubMedCrossRefGoogle Scholar
  11. 11.
    Petersen MEV, Chamberlain-Webber R, Fizpatrick AP, Ingram A, Williams T, Sutton R (1994) Permanent pacing for cardio-inhibitory malignant vasovagal syndrome. Br Heart J 71:274–281PubMedCrossRefGoogle Scholar
  12. 12.
    Connolly SJ, Sheldon R, Roberts RS, Gent M (1999) The North American vasovagal pacemaker study (VPS): a randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 33:16–20PubMedCrossRefGoogle Scholar
  13. 13.
    Benditt DG (1999) Cardiac pacing for prevention of vasovagal syncope. J Am Coll Cardiol 33:21–23 (editorial)PubMedCrossRefGoogle Scholar
  14. 14.
    Almquist A, Gornick CC, Benson DW Jr et al (1985) Carotid sinus hypersensitivity: evaluation of the vasodepressor component. Circulation 67:927–936CrossRefGoogle Scholar
  15. 15.
    Grubb BP, Kosinski D (1996) Current trends in etiology, diagnosis, and management of neurocardiogenic syncope. Curr Opin Cardiol 11:32–41PubMedCrossRefGoogle Scholar
  16. 16.
    Raviele A, Themistoclakis S, Gasparini G (1996) Drug treatment of vasovagal syncope. In: Blanc JJ, Benditt DG, Sutton R (eds) Neurally-mediated syncope: pathophysiology, investigations, and treatment. Futura, Armonk, NY, pp 113–117Google Scholar
  17. 17.
    Vasovagal Syncope International Study (VASIS) Group (1993) Double-blind randomised study of etilefrine versus placebo in patients with tilt-induced recurrent vasovagal syncope. Eur J Cardiac Pacing Electrophysiol 3:64Google Scholar
  18. 18.
    McTavish D, Goa KL (1989) Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 38:757–777PubMedCrossRefGoogle Scholar
  19. 19.
    Anonymous (1996) Midodrine hydrochloride: clinical investigator’s brochure. Roberts Pharmaceutical CorpGoogle Scholar
  20. 20.
    Gilden JL (1993) Midodrine in neurogenic orthostatic hypotension. Int Angiol 12:125–131PubMedGoogle Scholar
  21. 21.
    Low PA, Gilden JL, Freeman R, Sheng K-N, McElligott MA (1997) Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. JAMA 13:1046–1051CrossRefGoogle Scholar
  22. 22.
    Ward C, Kenny RA (1995) Observations on midodrine in a case of vasodepressor neurogenic syncope. Clin Autonom Res 5:257–260CrossRefGoogle Scholar
  23. 23.
    Sra J, Maglio C, Biehl M, Dhala A, Blanck Z, Deshpande S, Jazayeri MR, Akhtar M (1997) Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy. J Cardiovasc Electrophysiol 8:42–46PubMedCrossRefGoogle Scholar
  24. 24.
    Ward CR, Gray JC, Gilroy JJ, Kenny RA (1998) Midodrine: a role in the management of neurocardiogenic syncope. Heart 79:45–49PubMedGoogle Scholar
  25. 25.
    Benditt DG, Samniah N, Sakaguchi S, Fahy G, Wilbert L (1998) Midodrine is effective in patients with refractory neurally-mediated syncope. Circulation 98[Suppl I]:706 (abstr)Google Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • D. G. Benditt
    • 1
  • L. Wilbert
    • 1
  • G. Fahy
    • 1
  • S. Sakaguchi
    • 1
  • K. G. Lurie
    • 1
  • N. Samniah
    • 1
  1. 1.Cardiac Arrhythmia CenterUniversity of Minnesota Medical SchoolMinneapolisUSA

Personalised recommendations